4-(4-氯苯基)嘧啶-2-硫醇 | 175203-08-4

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-(4-氯苯基)嘧啶-2-硫醇
• 中文别名: 4-(4-氯苯基)嘧啶-2-巯基
• 英文名称: 4-(4-chlorophenyl)-2-pyrimidinethiol
• 英文别名: 4-(4-chlorophenyl)pyrimidine-2-thiol；6-(4-chlorophenyl)-1H-pyrimidine-2-thione
• CAS: 175203-08-4
• 化学式: C₁₀H₇ClN₂S
• mdl: MFCD00174262
• 分子量: 222.698
• InChiKey: TWKIWOOKHPWUIM-UHFFFAOYSA-N

物化性质

• 熔点：
  210 °C
• 沸点：
  357.1±52.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)
• 溶解度：
  26.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 包装等级：
  III
• 危险类别：
  8,6.1
• 危险性防范说明：
  P261,P280,P301+P310,P305+P351+P338
• 危险品运输编号：
  2923
• 危险性描述：
  H301,H315,H318,H335

SDS

Name:	4-(4-Chlorophenyl)pyrimidine-2-thiol, 97% Material Safety Data Sheet
Synonym:
CAS:	175203-08-4

Section 1 - Chemical Product MSDS Name: 4-(4-Chlorophenyl)pyrimidine-2-thiol, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175203-08-4	4-(4-Chlorophenyl)pyrimidine-2-thiol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Not available. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 175203-08-4: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: orange - yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 220 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H7ClN2S
Molecular Weight: 223

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acid chlorides, reducing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 175203-08-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(4-Chlorophenyl)pyrimidine-2-thiol - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 175203-08-4: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 175203-08-4 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 175203-08-4 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 4/04/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯基)嘧啶-2-硫醇 在 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 25.0h， 生成 N'-(4-(pyrrolidin-1-yl)benzylidene)-2-[(4-(4-chlorophenyl)pyrimidin-2-yl)thio]acetohydrazide
  参考文献：
  名称：

  Design, Synthesis, In vitro and In silico Evaluation of New Hydrazonebased Antitumor Agents as Potent Akt Inhibitors

  摘要：

  背景：Akt在多种人类癌症中过度表达或激活，包括胶质瘤、肺癌、乳腺癌、卵巢癌、胃癌和胰腺癌。Akt抑制导致细胞凋亡和肿瘤生长受到抑制，因此大量的工作致力于发现针对Akt的有效抗肿瘤药物。 目的：本研究的目的是鉴定针对Akt的有效抗癌剂。 方法：合成了新的腙类衍生物，并研究了它们对5RP7 H-ras致癌基因转化的大鼠胚胎成纤维细胞和L929小鼠胚胎成纤维细胞株的细胞毒性作用。此外，还使用流式细胞术评估了最活跃化合物对5RP7细胞株的凋亡作用。使用比色法研究了它们对Akt的抑制作用。还使用Schrödinger的Maestro分子建模软件进行了计算机模拟对接和吸收、分布、代谢和排泄（ADME）研究。 结果和讨论：化合物3a、3d、3g和3j在5RP7细胞上表现出良好的效果（IC50值分别为<0.97、<0.97、1.13±0.06和<0.97μg/mL），与顺铂（IC50=1.87±0.15μg/mL）相比。这四个化合物被确定为能够显著诱导5RP7细胞株的凋亡。其中，N'-苄基亚甲基-2-[(4-（4-甲氧基苯基）嘧啶-2-基）硫]乙酰肼（3g）在抑制Akt方面表现出显著的效果（IC50=0.5±0.08μg/mL），与GSK690693（IC50=0.6±0.05μg/mL）相比。对接研究表明，化合物3g与Akt的活性位点（PDB代码：2JDO）具有良好的亲和力。根据计算机模拟的ADME研究，该化合物也符合Lipinski的五项规则和Jorgensen的三项规则。 结论：化合物3g是一种潜在的口服可用的针对Akt的细胞毒性剂和凋亡诱导剂。

  DOI：

  10.2174/1570180817999200618163507
• 作为产物：
  描述：

  (2E)-3-(dimethylamino)-1-(4-chlorophenyl)prop-2-en-1-one 、 硫脲 、 potassium carbonate 在 水 、 hexanes 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 4-(4-氯苯基)嘧啶-2-硫醇
  参考文献：
  名称：

  Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto

  摘要：

  本发明揭示了具有IKK抑制剂活性的化合物，特别是IKK-2。本发明的化合物是具有以下结构的苯胺嘧啶衍生物：其中R1和R6如定义所述。这种化合物在治疗对IKK抑制有反应的广泛疾病方面具有用途。因此，本发明还揭示了治疗这种疾病的方法，以及含有上述化合物中的一个或多个化合物的制药组合物。

  公开号：

  US07442699B2

文献信息

• Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20030220330A1

  公开（公告）日：2003-11-27

  Compounds having activity as inhibitors of the JNK pathway are disclosed. The compounds of this invention are anilinopyrimidine derivatives having the following structure: 1 wherein R 1 through R 6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明揭示了作为JNK通路抑制剂活性的化合物。本发明的化合物是具有以下结构的苯胺吡嘧啶衍生物：其中R1至R6如本文所定义。这些化合物在治疗对JNK通路抑制敏感的广泛疾病方面具有用途。因此，本文还揭示了治疗这些疾病的方法，以及含有上述化合物中的一个或多个化合物的药物组合物。
• Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
  申请人：——

  公开号：US20040106634A1

  公开（公告）日：2004-06-03

  This invention generally relates to methods for treating or preventing a condition responsive to JNK inhibition, such as a metabolic condition, comprising administering to a patient in need thereof an effective amount of an Anilinopyrimidine Derivative having the following structure: 1 or a pharmaceutically acceptable salt thereof, wherein R 1 through R 6 are as defined herein.

  这项发明通常涉及用于治疗或预防对JNK抑制敏感的疾病的方法，例如代谢状况，包括向需要的患者施用具有以下结构的Anilinopyrimidine衍生物的有效剂量：1或其药用可接受盐，其中R1至R6如本文所定义。
• Small molecule inhibitors of caspases
  申请人：——

  公开号：US20030114447A1

  公开（公告）日：2003-06-19

  The present invention provides compounds having formula (I): 1 and pharmaceutically acceptable derivatives thereof, wherein A, B, D, E, G, J, n, and R 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof as caspase inhibitors and for the treatment of disorders caused by excessive apoptotic activity.

  本发明提供了具有式（I）的化合物及其药学上可接受的衍生物，其中A、B、D、E、G、J、n和R1如本文中一般描述和分类，此外还提供了其制药组合物以及用作caspase抑制剂和治疗由过度凋亡活动引起的疾病的方法。
• Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
  申请人：Catalano George John

  公开号：US20050054819A1

  公开（公告）日：2005-03-10

  Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

  本文介绍了环状酰胺类酮衍生物，其作为卡他普星K抑制剂具有用途。所述发明还包括制备这种环状酰胺类酮衍生物的方法，以及使用它们治疗与增强骨转换相关的疾病（包括骨质疏松症），最终可导致骨折的方法。
• CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS
  申请人：Catalano George John

  公开号：US20080058333A1

  公开（公告）日：2008-03-06

  Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

  本文描述了环状烷基酮酰胺衍生物，其作为猫hepsin K抑制剂具有用途。所述发明还包括制备这种环状烷基酮酰胺衍生物的方法，以及使用它们治疗与增强骨转换相关的疾病的方法，包括骨质疏松症，最终可能导致骨折。